QIAGEN N.V.

491 articles with QIAGEN N.V.

• Sysmex Inostics & QIAGEN Highlight Cancer Companion Diagnostics Alliance at ASCO 2022

  6/2/2022

  Sysmex Inostics, Inc. and QIAGEN N.V. will co-exhibit at the 2022 ASCO Annual Meeting, the world's largest clinical cancer research meeting, held June 3, 2022, through June 7, 2022, in Chicago.

• U.S. CDC Endorses the Use of Digital PCR Technology for Wastewater Surveillance of Infectious Diseases – Including COVID-19 Outbreaks

  6/1/2022

  QIAGEN N.V. announced that it welcomed an endorsement from the National Wastewater Surveillance System of the U.S. Centers for Disease Control and Prevention and their validation and approval for the use of two digital PCR systems – including the QIAcuity digital PCR system – for wastewater surveillance of 30 pathogens, including the SARS-CoV-2 virus.

• QIAGEN’s Eco-Friendlier Products Earn Prestigious ACT Label

  5/19/2022

  QIAGEN N.V. announced that its recently launched, environmentally friendlier QIAwave nucleic-acid extraction kits have received the prestigious ACT Environmental Impact Factor Label from My Green Lab, a non-profit organization dedicated to advancing sustainability in scientific research.

• QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels

  5/16/2022

  QIAGEN N.V. announced the launch of QIAstat-Dx Rise – a high-capacity version of the QIAstat-Dx automated syndromic system – and enhancements to the menu of tests for the fully integrated one-step molecular testing solution that provides results in about one hour.

• QIAGEN Acquires Majority Stake in Enzymes Provider BLIRT S.A.

  5/11/2022

  QIAGEN N.V. announced that it has signed agreements to acquire a 96% majority ownership stake in BLIRT SA, a manufacturer of recombinant enzymes for the life science industry based in Gdansk, Poland.

• QIAGEN Proposes Expansion of Supervisory Board

  5/11/2022

  QIAGEN N.V. announced the proposal of Dr. Eva Pisa, a leader in health diagnostics and biotechnology who has extensive experience from start-ups to corporate companies, as a new member of the Supervisory Board.

• QIAGEN Adds HSV1/2 Herpes Assay With CE-IVD Certification for Use on NeuMoDx Integrated PCR System

  5/5/2022

  QIAGEN N.V. announced that its NeuMoDx HSV 1/2 Quant Assay for the quantification and differentiation of herpes simplex virus type 1 DNA and/or herpes simplex virus type 2 has received CE-IVD certification for the European Union and other countries that accept this marking.

• QIAGEN exceeds outlook for Q1 2022, delivers strong 14% CER sales growth from non-COVID products and increases full-year outlook

  4/26/2022

  QIAGEN N.V. announced results for the first quarter of 2022 and increased the outlook for full-year 2022.

• QIAGEN N.V. to release results for Q1 2022 and hold Webcast

  4/20/2022

  QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release results for the first quarter of 2022 on Wednesday, April 27, at approximately 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.

• QIAGEN Reaches Milestone With 100 Million QuantiFERON Tests Used to Detect TB

  3/24/2022

  QIAGEN N.V. marked World TB Day by announcing its QuantiFERON blood test has been used to screen patients for tuberculosis infection more than 100 million times since its launch – an achievement that cements its status as the gold standard in the fight against this contagious and often deadly disease.

• QIAGEN Announces 20-F Annual Report Filing for 2021 Results

  3/14/2022

  QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2021, with the U.S. Securities and Exchange Commission.

• QIAGEN’s New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation

  2/7/2022

  QIAGEN N.V. announced that its QuantiFERON tuberculosis testing solution has gained additional momentum with the approval of the fourth generation of this modern gold standard test in China and a new endorsement from the World Health Organization.

• QIAGEN Completes U.S. Federal Contract to Equip Local Public Health Authorities with QIAcuity Digital PCR System for COVID-19 Surveillance

  1/25/2022

  QIAGEN N.V. announced it has completed a U.S. government contract to equip public health laboratories across the country with the QIAcuity digital PCR system to monitor the spread of the COVID-19 pandemic by testing wastewater for the presence of SARS-CoV-2 pathogens.

• QIAGEN N.V. to release results for Q4 2021 and Full-Year of 2021

  1/19/2022

  QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the fourth quarter and full-year results of 2021 on Tuesday, February 8, at approximately 16:05 Eastern Standard Time (EST)

• QIAGEN Launches QIAwave Portfolio of Environmentally Friendly Products

  1/18/2022

  QIAGEN N.V. announced its new QIAwave product line by launching three nucleic acid extraction kits that use fewer components and produce less waste than existing ones.

• QIAGEN expands QIAstat-Dx syndromic testing menu and announces launch plans for new QIAstat-Dx Rise higher-throughput version

  1/10/2022

  QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced important enhancements in the commercialization of its QIAstat-Dx syndromic testing solution – which enables laboratories and hospitals worldwide to test patients for multiple pathogens from one sample – with new tests and the launch of a higher-throughput version that includes a new level of walk-away efficiency through the new QIAstat-Dx Smart Drawer.

• QIAGEN Strengthens Growing Portfolio of Applications for Its Digital PCR Platform QIAcuity With New Collaborations

  1/7/2022

  QIAGEN N.V. announced new additions to the growing number of applications for QIAcuity, its ultrasensitive digital PCR platform that has set new standards by using so-called nanoplates to process samples in two hours rather than the five hours required by other systems.

• QIAGEN Expands QuantiFERON Portfolio in the Fight Against TB

  1/6/2022

  QIAGEN N.V. announced important expansion initiatives for its QuantiFERON franchise, building on its status as the gold standard for detection of tuberculosis, while developing new applications for this technology designed to detect potentially deadly latent diseases.

• QIAGEN Launches CE-marked Version of QuantiFERON® SARS-CoV-2 to Assess T-cell Response to COVID-19

  12/2/2021

  QIAGEN N.V. announced the CE marking of its QuantiFERON® SARS-CoV-2 assay that measures T-cell responses to SARS-CoV-2 and aids in the assessment of immunity in individuals who have received COVID-19 vaccination.

• QIAGEN reaffirms effectiveness of its SARS-CoV-2 PCR tests in light of the new coronavirus variant B.1.1.529

  11/26/2021

  QIAGEN N.V. announced its polymerase chain reaction tests remain accurate and effective in detecting SARS-CoV-2 infections in light of the emergence of a new variant of concern detected in South Africa.